- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077700
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-288 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-288 in approximately 210 adults with schizophrenia. Subjects will be randomized to one of three treatment groups (ABT-288 Dose 1, ABT-288 Dose 2 or placebo) for a 12-week Treatment Period. The purpose of this research study is to find out whether ABT-288 compared to placebo can improve cognition and what side effects ABT 288 may cause. Cognition is the way a person thinks, and it includes abilities like paying attention, focusing, remembering things, and solving problems. Acronyms listed in the Outcomes and/or Eligibility sections for this study are defined below:
- MCCB: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery
- UPSA-2: University of California at San Diego (UCSD) Performance-Based Skills Assessment-2
- CANTAB: Cambridge Neuropsychological Test Automated Battery
- PANSS: Positive and Negative Syndrome Scale
- NSA-16: Negative Symptom Assessment-16
- CGI-S: Clinical Global Impression - Severity
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Anaheim, California, United States, 92804
- Site Reference ID/Investigator# 21662
-
Garden Grove, California, United States, 92845
- Site Reference ID/Investigator# 21683
-
National City, California, United States, 91950
- Site Reference ID/Investigator# 21581
-
Norwalk, California, United States, 90650
- Site Reference ID/Investigator# 45310
-
Pasadena, California, United States, 91106
- Site Reference ID/Investigator# 26400
-
Pico Rivera, California, United States, 90660
- Site Reference ID/Investigator# 21584
-
Riverside, California, United States, 92506
- Site Reference ID/Investigator# 45312
-
San Diego, California, United States, 92128
- Site Reference ID/Investigator# 45309
-
-
Florida
-
Plantation, Florida, United States, 33317
- Site Reference ID/Investigator# 46603
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Site Reference ID/Investigator# 21681
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71104-2136
- Site Reference ID/Investigator# 26397
-
-
Massachusetts
-
Pittsfield, Massachusetts, United States, 01201
- Site Reference ID/Investigator# 21761
-
-
Missouri
-
Saint Louis, Missouri, United States, 63139
- Site Reference ID/Investigator# 21591
-
-
New York
-
Brooklyn, New York, United States, 11235
- Site Reference ID/Investigator# 26409
-
Cedarhurst, New York, United States, 11516
- Site Reference ID/Investigator# 21588
-
-
Ohio
-
Dayton, Ohio, United States, 45417
- Site Reference ID/Investigator# 21589
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
- Site Reference ID/Investigator# 26407
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19131
- Site Reference ID/Investigator# 21601
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Site Reference ID/Investigator# 26399
-
-
Texas
-
Austin, Texas, United States, 78731
- Site Reference ID/Investigator# 21590
-
Austin, Texas, United States, 78754
- Site Reference ID/Investigator# 21582
-
DeSoto, Texas, United States, 75115
- Site Reference ID/Investigator# 26406
-
Houston, Texas, United States, 77008
- Site Reference ID/Investigator# 26402
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Site Reference ID/Investigator# 27502
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview.
- Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial Screening Visit; taking same antipsychotic medication(s) for at least 8 weeks prior to the Day -1 visit; core positive symptoms of PANSS no worse than moderate in severity throughout Screening Period of at least 4 weeks.
- Has been diagnosed with or treated for schizophrenia for at least 2 years prior to Initial Screening Visit.
- Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to Initial Screening Visit.
- Has an identified responsible contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject and ensure compliance with protocol requirements.
Exclusion Criteria:
- Has valid current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, posttraumatic stress disorder, obsessive compulsive disorder, or a current major depressive episode.
- Has history of substance abuse (excluding nicotine or tobacco products) or alcohol abuse within 6 months prior to Screening Visit; has a substance dependence disorder (excluding nicotine or tobacco products) that has not been remitted for at least 1 year prior to Initial Screening Visit.
- Is taking any medication for extrapyramidal symptoms at any time from the Initial Screening Visit until the Day -1 Visit.
- Is taking any antidepressant that is excluded, including tricyclic antidepressants and monoamine oxidase inhibitors, at any time from 8 weeks prior to the Day -1 Visit.
- Has significant suicidal ideation at Initial Screening Visit.
- Has had a suicide attempt within 1 year prior to the Day -1 Visit.
- Has participated in another trial utilizing the MATRICS Consensus Cognitive Battery (MCCB) or UCSD Performance-Based Skills Assessment (UPSA) (any version) within 6 months prior to Initial Screening Visit.
- Is currently enrolled in any form of cognitive remediation training.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABT-288 Dose 1
low dose of ABT-288
|
|
Experimental: ABT-288 Dose 2
high dose of ABT-288
|
|
Placebo Comparator: Sugar Pill
inactive substance
|
inactive substance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cognition: MCCB
Time Frame: Measurements from screening period through 12-week treatment period
|
Measurements from screening period through 12-week treatment period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Functioning: UPSA-2
Time Frame: Measurements from screening period through 12-week treatment period
|
Measurements from screening period through 12-week treatment period
|
Cognition: CANTAB
Time Frame: Measurements from screening period through 12-week treatment period
|
Measurements from screening period through 12-week treatment period
|
Symptom Severity: PANSS, NSA-16, CGI-S
Time Frame: Measurements from screening period through 12-week treatment period
|
Measurements from screening period through 12-week treatment period
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20.
- Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull. 2014 Nov;40(6):1433-42. doi: 10.1093/schbul/sbt240. Epub 2014 Feb 10.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M10-503
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Deficits in Schizophrenia
-
AbbVie (prior sponsor, Abbott)CompletedCognitive Deficits in SchizophreniaUnited States
-
Shanghai Mental Health CenterXuhui Mental Health CenterRecruitingSchizophrenia | Cognitive Impairment | Repetitive Transcranial Magnetic Stimulation | Negative Symptoms in Schizophrenia | Dorsolateral Prefrontal CortexChina
-
National Institute of Mental Health (NIMH)University of PittsburghWithdrawnCognitive Deficits Related to Internet UseUnited States
-
Lithuanian University of Health SciencesRecruitingSchizophrenia | Cognitive Deficit | Negative Symptoms in Schizophrenia | Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)Lithuania
-
University of OttawaThe Ottawa HospitalUnknownFirst Episode SchizophreniaCanada
-
Centre for Addiction and Mental HealthCompletedSchizophrenia | Cognitive Deficit | Cognitive Remediation | Functional Impairment | Late Life SchizophreniaCanada
-
Tongji UniversityRecruiting
-
AbbVie (prior sponsor, Abbott)CompletedSchizophreniaUnited States, Russian Federation, United Kingdom
-
Shanghai Mental Health CenterNathan Kline Institute for Psychiatric ResearchCompleted
-
Birte GlenthojPfizer; Rigshospitalet, Denmark; Glostrup University Hospital, CopenhagenTerminatedSchizophreniaDenmark
Clinical Trials on ABT-288 Low Dose
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States